Export

You can select particular sections to be included in the output file.

Model List of Essential Medicines

Found 1098 recommendations for 557 medicines and 44 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
  1. Abacavir General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 60 mg tablet (dispersible, scored) (as sulfate); 300 mg tablet (as sulfate)
  2. Abacavir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
  3. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
  4. Acetazolamide General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
  5. Acetic acid General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% in alcohol
  6. Acetylcysteine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
  7. Acetylsalicylic acid General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 300 to 500 mg
    Indications
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Section
    Juvenile joint diseases
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
  8. Aciclovir General information
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
  9. Activated charcoal General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Other: powder
  10. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL
  11. Afatinib General information
    Section
    Targeted therapies
  12. Albendazole General information
    Section
    Antifilarials
    • Oral > Solid: 400 mg tablet (chewable)
    Indications
    Section
    Intestinal anthelminthics
    • Oral > Solid: 400 mg tablet (chewable)
  13. Alcohol based hand rub General information
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
  14. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
  15. Allopurinol General information
    Section
    Supportive medicines
    • Oral > Solid: 100 mg tablet; 300 mg tablet
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
  16. Alteplase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
  17. Amidotrizoate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
  18. Amikacin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection (as sulfate); 500 mg in vial powder for injection (as sulfate); 100 mg in vial powder for injection (as sulfate)
  19. Amiloride General information
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
  20. Amiodarone General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
  21. Amitriptyline General information
    Section
    Medicines used in depressive disorders
    • Oral > Solid: 25 mg; 75 mg
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 25 mg; 10 mg; 75 mg
    Indications
  22. Amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
  23. Amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
  24. Amodiaquine + sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
    Indications
  25. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
  26. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    Section
    Antituberculosis medicines
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
  27. Amphotericin b General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
  28. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
  29. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
  30. Anti-d immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
  31. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
  32. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
  33. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera and immunoglobulins
    • Parenteral > General injections > IV:
  34. Apixaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism
  35. Aprepitant General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid: 80 mg; 125 mg; 165 mg
  36. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
  37. Artemether General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection)
  38. Artemether + lumefantrine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
  39. Artesunate General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
    • Oral > Solid: 50 mg tablet
    • Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
  40. Artesunate + amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
  41. Artesunate + mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
  42. Artesunate + pyronaridine tetraphosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
  43. Ascorbic acid General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
  44. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
  45. Atazanavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
  46. Atazanavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
  47. Atenolol General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  48. Atorvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  49. Atracurium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
  50. Atropine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
  51. Azathioprine General information
    Section
    Disease-modifying agents used in rheumatoid disorders (DMARDs)
    • Oral > Solid: 50 mg
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)
    • Oral > Solid: 50 mg
  52. Azithromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
  53. Barium sulfate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
    Indications
  54. Bcg vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  55. Beclometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
    Indications
  56. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet
  57. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
  58. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
  59. Benznidazole General information
    Section
    American trypanosomiasis
    • Oral > Solid: 100 mg tablet; 50 mg tablet (scored); 12.5 mg tablet
    Indications
  60. Benzoyl peroxide General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
  61. Benzyl benzoate General information
    Section
    Dermatological medicines (topical) > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
  62. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
  63. Betamethasone General information
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
  64. Bevacizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
  65. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
  66. Biperiden General information
    Section
    Antiparkinsonism medicines
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
  67. Bisoprolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
  68. Bleomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
  69. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
  70. Budesonide General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 100 µg per dose
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
    Indications
  71. Budesonide + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
    Indications
  72. Bupivacaine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
    Indications
  73. Caffeine citrate General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
  74. Calamine General information
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
  75. Calcium General information
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
  76. Calcium gluconate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
  77. Carbamazepine General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable)
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 100 mg scored; 200 mg scored
  78. Carbetocin General information
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
  79. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  80. Carvedilol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  81. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate)
  82. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
  83. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
  84. Cefotaxime General information
  85. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
  86. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
  87. Ceftriaxone General information
  88. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
  89. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  90. Chlorambucil General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
  91. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
  92. Chlorhexidine General information
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
  93. Chlorine base compound General information
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
  94. Chloroquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Section
    Disease-modifying agents used in rheumatoid disorders (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
  95. Chloroxylenol General information
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
  96. Chlorpromazine General information
    Section
    Medicines used in psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
  97. Cholera vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  98. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Solid: 25 mg
  99. Ciprofloxacin General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid: 250 mg (as hydrochloride)
  100. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Solid: 500 mg
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
  101. Clindamycin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
  102. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
  103. Clomifene General information
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
  104. Clomipramine General information
    Section
    Medicines used for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
  105. Clopidogrel General information
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
  106. Clotrimazole General information
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
  107. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
  108. Clozapine General information
    Section
    Medicines used in psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
  109. Coagulation factor ix complex General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
  110. Coagulation factor viii General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection
    Indications
  111. Coal tar General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
  112. Codeine General information
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
  113. Colecalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
  114. Colistin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
  115. Compound sodium lactate solution General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
  116. Copper-containing intrauterine device General information
  117. Cyclizine General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 50 mg tablet
    • Parenteral > General injections > unspecified: 50 mg per mL
    Indications
  118. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
  119. Cytarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
  120. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
  121. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
  122. Daclatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
  123. Dactinomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 µg in vial powder for injection
  124. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  125. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
  126. Darbepoetin alfa General information
    Section
    Antianaemia medicines
  127. Darunavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
  128. Dasabuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 250 mg tablet
  129. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
  130. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
  131. Deferoxamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
  132. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg tablet
  133. Dengue vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  134. Desmopressin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 10 µg per dose (acetate)
  135. Dexamethasone General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
    • Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
  136. Dextran 70 General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
  137. Diazepam General information
    Section
    Anticonvulsants/antiepileptics
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
    • Local > Rectal > Solution: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 5 mg; 10 mg
    • Local > Rectal > Solution: 2.5 mg; 5 mg; 10 mg
    • Parenteral > General injections > unspecified: 5 mg per mL
    Indications
  138. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
  139. Diethylcarbamazine General information
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
  140. Digoxin General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
  141. Dihydroartemisinin + piperaquine phosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
  142. Diloxanide General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
  143. Dimercaprol General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
  144. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera and immunoglobulins
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
  145. Diphtheria vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  146. Docetaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
  147. Docusate sodium General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg capsule
    Indications
  148. Dolutegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet
  149. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  150. Dopamine General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
  151. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Solid: 100 mg (as hyclate)
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
  152. Edoxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism
  153. Efavirenz General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet; 200 mg scored tablet
  154. Efavirenz + emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  155. Efavirenz + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
  156. Eflornithine General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 100 mL bottle (hydrochloride)
  157. Emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  158. Enalapril General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
    Section
    Medicines used in heart failure
    • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
    Indications
  159. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
  160. Entecavir General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
  161. Ephedrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
    Indications
  162. Epinephrine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
  163. Epoetin alfa General information
    Section
    Antianaemia medicines
  164. Epoetin beta General information
    Section
    Antianaemia medicines
  165. Epoetin theta General information
    Section
    Antianaemia medicines
  166. Ergocalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
  167. Ergometrine General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
  168. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
  169. Erythromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
  170. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
  171. Estradiol cypionate + medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
  172. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  173. Ethambutol General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 25 mg per mL
    • Oral > Solid: 100 to 400 mg tablet (hydrochloride); 100 mg dispersible tablet
    Indications
  174. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
  175. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
  176. Ethanol General information
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
  177. Ethinylestradiol + levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 µg + 150 µg
  178. Ethinylestradiol + norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
  179. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 125 mg tablet; 250 mg tablet; 125 mg tablet (dispersible)
  180. Ethosuximide General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
  181. Etonogestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
  182. Fentanyl General information
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
  183. Ferrous salt General information
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL iron (as sulfate)
    • Oral > Solid: 60 mg iron
  184. Ferrous salt + folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 60 mg iron + 400 µg tablet
  185. Fexinidazole General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 600 mg
  186. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
  187. Fluconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 50 mg capsule
  188. Flucytosine General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
  189. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
  190. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 100 µg (acetate)
  191. Fluorescein General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
  192. Fluorouracil General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
  193. Fluoxetine General information
    Section
    Medicines used in depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
  194. Fluphenazine General information
    Section
    Medicines used in psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
    Indications
  195. Fluvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  196. Folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    • Oral > Solid: 400 µg
  197. Fomepizole General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
  198. Fosfomycin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
  199. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  200. Furosemide General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL
    • Oral > Solid: 40 mg; 10 mg; 20 mg
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL
    • Oral > Solid: 40 mg
    Indications
  201. Gefitinib General information
    Section
    Targeted therapies
  202. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
  203. Gentamicin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
  204. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 100 mg + 40 mg tablet
    Indications
  205. Gliclazide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
  206. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL
  207. Glucose General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
  208. Glucose + sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
  209. Glutaral General information
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
  210. Glyceryl trinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
  211. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  212. Griseofulvin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
  213. Haemophilus influenzae type b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  214. Haloperidol General information
    Section
    Medicines used in psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 2 mg; 0.5 mg; 5 mg
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
  215. Halothane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
  216. Heparin sodium General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
  217. Hepatitis a vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  218. Hepatitis b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  219. Hpv vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  220. Hydralazine General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
  221. Hydrochlorothiazide General information
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Section
    Diuretics
    • Oral > Solid: 25 mg
    Indications
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
  222. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema:
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
  223. Hydromorphone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  224. Hydroxocobalamin General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
  225. Hydroxycarbamide General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid: 200 mg; 500 mg; 1 g
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
  226. Hydroxychloroquine General information
    Section
    Disease-modifying agents used in rheumatoid disorders (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
  227. Hyoscine butylbromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
  228. Hyoscine hydrobromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
  229. Ibuprofen General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
  230. Ifosfamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
  231. Imatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg tablet; 400 mg tablet
  232. Indometacin General information
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen for Patent arterial duct
  233. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  234. Influenza vaccine (seasonal) General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  235. Insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble)
  236. Intermediate-acting insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin
  237. Intraperitoneal dialysis solution General information
    Section
    Peritoneal dialysis solution
    • parenteral solution
  238. Iodine General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
    • Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
    • Oral > Solid: 190 mg
  239. Iohexol General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
    Indications
  240. Ipratropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 20 µg per dose
  241. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
  242. Isoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
  243. Isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 100 to 300 mg tablet; 50 mg tablet (scored); 100 mg tablet (dispersible)
    Indications
  244. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible); 75 mg + 400 mg + 150 mg tablet
    Indications
  245. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
  246. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
    Indications
  247. Isosorbide dinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
  248. Ivermectin General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 3 mg tablet (scored)
    Section
    Antifilarials
    • Oral > Solid: 3 mg tablet (scored)
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid: 3 mg tablet (scored)
    Indications
  249. Japanese encephalitis vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
  250. Ketamine General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
  251. Lactulose General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
    Indications
  252. Lamivudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
  253. Lamivudine + nevirapine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
  254. Lamivudine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
  255. Lamotrigine General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
  256. Latanoprost General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
  257. Ledipasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
  258. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
  259. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
  260. Levamisole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 50 mg tablet; 150 mg tablet (as hydrochloride)
    Indications
  261. Levodopa + carbidopa General information
    Section
    Antiparkinsonism medicines
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
  262. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
  263. Levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 µg
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
  264. Levonorgestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
  265. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
  266. Lidocaine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
    Indications
  267. Lidocaine + epinephrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
    Indications
  268. Linezolid General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet; 150 mg tablet (dispersible)
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
  269. Lisinopril + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
  270. Lisinopril + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
  271. Lithium carbonate General information
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 300 mg
  272. Loperamide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 2 mg solid oral dosage form
    Indications
  273. Lopinavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Liquid: 400 mg + 100 mg per 5 mL
    • Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg
  274. Loratadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL oral liquid
    • Oral > Solid: 10 mg tablet
  275. Lorazepam General information
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
  276. Losartan General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
  277. Lovastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  278. Lugol's solution General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
    Indications
  279. Magnesium sulfate General information
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
  280. Mannitol General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
  281. Measles vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  282. Mebendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 100 mg tablet (chewable); 500 mg tablet (chewable)
  283. Medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Section
    Progestogens
    • Oral > Solid: 5 mg
  284. Mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
  285. Meglumine antimoniate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 30% in 5 mL ampoule equivalent to approximately 8.1% antimony
  286. Meglumine iotroxate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
    Indications
  287. Melarsoprol General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
  288. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
  289. Meningococcal meningitis vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  290. Mercaptopurine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg tablet
  291. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
  292. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
  293. Mesalazine General information
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine for Crohn disease site Therapeutic equivalent to sulfasalazine for Ulcerative colitis
  294. Metformin General information
    Section
    Medicines for diabetes
    • xyx
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
  295. Methadone General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (as hydrochloride); 10 mg per 5 mL (as hydrochloride); 5 mg per mL concentrate for oral liquid (as hydrochloride); 10 mg per mL concentrate for oral liquid (as hydrochloride)
    • Oral > Solid: 5 mg (as hydrochloride); 10 mg (as hydrochloride)
  296. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
  297. Methotrexate General information
    Section
    Disease-modifying agents used in rheumatoid disorders (DMARDs)
    • Oral > Solid: 2.5 mg (as sodium salt)
  298. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
  299. Methyldopa General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
  300. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
  301. Methylthioninium chloride General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
  302. Metoclopramide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
  303. Metoprolol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  304. Metronidazole General information
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    Indications
  305. Miconazole General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
  306. Midazolam General information
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 15 mg tablet; 7.5 mg tablet
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (for buccal administration); 10 mg per mL in ampoule (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL solution for oromucosal administration; 10 mg per mL solution for oromucosal administration
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL oral liquid
    • Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
    • Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection
    Indications
  307. Mifepristone - misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
  308. Miltefosine General information
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
  309. Misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 µg
    • Local > Vaginal > tablet: 25 µg
  310. Morphine General information
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
    • Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
    • Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)
  311. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
  312. Multiple micronutrient powder General information
    Section
    Vitamins and minerals
    • Oral > Other:
  313. Mumps vaccine General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  314. Mupirocin General information
    Section
    Dermatological medicines (topical) > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
  315. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  316. Naloxone General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
  317. Natamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
  318. Neostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Oral > Solid: 15 mg (neostigmine bromide)
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
  319. Nevirapine General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL oral solution
    • Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)
  320. Niclosamide General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
  321. Nicotinamide General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
  322. Nicotine replacement therapy General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Other: 2 mg chewing gum; 4 mg chewing gum
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
  323. Nifedipine General information
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
  324. Nifurtimox General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 120 mg
    Section
    American trypanosomiasis
    • Oral > Solid: 30 mg tablet; 120 mg tablet; 250 mg tablet
    Indications
  325. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
  326. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg tablet
    Indications
  327. Nitrous oxide General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
  328. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
  329. Norethisterone General information
    Section
    Progestogens
  330. Norethisterone enantate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
  331. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
  332. Nystatin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL; 50 mg per 5 mL
    • Oral > Solid: 500000 IU tablet; 100000 IU lozenge; 100000 IU tablet
    • Local > Topical > Other: 100000 IU pessary
    Indications
  333. Ofloxacin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
  334. Ombitasvir + paritaprevir + ritonavir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
  335. Omeprazole General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
    • Oral > Solid: 10 mg; 20 mg; 40 mg
    • Parenteral > General injections > IV: 40 mg in vial
  336. Ondansetron General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
    Indications
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
  337. Oral rehydration salts General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
  338. Oral rehydration salts - zinc sulfate General information
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
    Indications
  339. Oseltamivir General information
    Section
    Other antivirals
    • Oral > Liquid: 12 mg per mL powder for oral liquid
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
  340. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
  341. Oxamniquine General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg capsule
  342. Oxycodone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  343. Oxygen General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Section
    Medical gases
    • Respiratory > Inhalation:
  344. Oxytocin General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
  345. P-aminosalicylic acid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 500 mg tablet; 4 g granules in sachet
  346. Pancreatic enzymes General information
    Section
    Pancreatic enzymes
    • Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
  347. Paracetamol General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
    • Oral > Solid: 300 to 500 mg
    Indications
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 100 mg
    Indications
  348. Paromomycin General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
  349. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial
  350. Pegylated interferon alfa (2a) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
  351. Pegylated interferon alfa (2b) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
  352. Pembrolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to nivolumab for Melanoma of skin
  353. Penicillamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Section
    Disease-modifying agents used in rheumatoid disorders (DMARDs)
    • Oral > Solid: 250 mg
  354. Pentamidine General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 200 mg (as isetionate) powder for injection
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 200 mg tablet; 300 mg tablet
    Indications
  355. Permethrin General information
    Section
    Dermatological medicines (topical) > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
  356. Pertussis vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  357. Phenobarbital General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid: 15 to 100 mg
    • Parenteral > General injections > IV: 200 mg per mL in ampoule (phenobarbital sodium)
  358. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt) tablet
    • Oral > Solid: 250 mg (as potassium salt)
  359. Phenytoin General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 25 to 30 mg per 5 mL
    • Oral > Solid: 25 mg (sodium salt); 100 mg (sodium salt); 50 mg (sodium salt); 50 mg chewable tablet
    • Parenteral > General injections > unspecified: 50 mg per mL in 5 vial (sodium salt)
  360. Phytomenadione General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
    • Oral > Solid: 10 mg tablet
  361. Pilocarpine General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
  362. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
  363. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  364. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL (Injection)
  365. Pneumococcal vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  366. Podophyllotoxin General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin for Plantar warts Therapeutic equivalent to podophyllum resin for Anogenital warts
  367. Podophyllum resin General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
  368. Poliomyelitis vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  369. Polygeline General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    Indications
    Therapeutic equivalent to dextran 70 for Hypovolaemia
  370. Polymyxin b General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 500000 IU in vial powder for injection
  371. Potassium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
  372. Potassium ferric hexacyanoferrate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
  373. Potassium iodide General information
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 60 mg
    Indications
  374. Potassium permanganate General information
    Section
    Dermatological medicines (topical) > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
  375. Povidone iodine General information
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
  376. Pravastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  377. Praziquantel General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 600 mg tablet; 150 mg tablet
    • Oral > Solid: 600 mg tablet
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid: 600 mg tablet
  378. Prednisolone General information
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Retention enema:
    Indications
    Therapeutic equivalent to hydrocortisone for Crohn disease site Therapeutic equivalent to hydrocortisone for Ulcerative colitis
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
  379. Primaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
  380. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
  381. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    Indications
  382. Progesterone vaginal ring General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
  383. Proguanil General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg tablet (hydrochloride)
  384. Propofol General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 10 mg per mL; 20 mg per mL
  385. Propranolol General information
    Section
    Antimigraine medicines > For prophylaxis
    • Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
    Indications
  386. Propylthiouracil General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
  387. Prostaglandin e1 General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
  388. Prostaglandin e2 General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
  389. Protamine sulfate General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
  390. Pyrantel General information
    Section
    Intestinal anthelminthics
    • Oral > Liquid: 50 mg per mL (as embonate or pamoate)
    • Oral > Solid: 250 mg chewable tablet (as embonate or pamoate)
  391. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 30 mg per mL
    • Oral > Solid: 400 mg tablet; 150 mg tablet (dispersible); 150 mg tablet (scored)
    Indications
  392. Pyridostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
    • Oral > Solid: 60 mg (pyridostigmine bromide)
  393. Pyridoxine General information
    Section
    Vitamins and minerals
    • Oral > Solid: 25 mg (hydrochloride)
  394. Pyrimethamine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
  395. Quinine General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
    • Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
  396. Rabies vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  397. Raltegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable); 100 mg tablet (chewable)
    • Oral > Other: 100 mg granules for oral suspension
  398. Ranitidine General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
  399. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
  400. Red blood cells General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  401. Retinol General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
    • Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
    • Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule
  402. Ribavirin General information
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
  403. Riboflavin General information
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
  404. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
  405. Rifampicin General information
    Section
    Antileprosy medicines
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
  406. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg tablet
  407. Risperidone General information
    Section
    Medicines used in psychotic disorders
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
  408. Ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Liquid: 400 mg per 5 mL
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
    • Oral > Other: 100 mg powder
  409. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
  410. Rivaroxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism
  411. Rotavirus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  412. Rubella vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  413. Salbutamol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
    • Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
  414. Salicylic acid General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
  415. Selenium sulfide General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
  416. Senna General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
  417. Silver sulfadiazine General information
    Section
    Dermatological medicines (topical) > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
  418. Simvastatin General information
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
  419. Sodium calcium edetate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
  420. Sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
  421. Sodium fluoride General information
    Section
    Vitamins and minerals
    • In any appropriate topical formulation
    Indications
  422. Sodium hydrogen carbonate General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
  423. Sodium nitrite General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
  424. Sodium nitroprusside General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
  425. Sodium stibogluconate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
  426. Sodium thiosulfate General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Solution: 15%
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
  427. Sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg tablet
  428. Sofosbuvir + velpatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg + 100 mg tablet
    Indications
  429. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
  430. Spironolactone General information
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Section
    Diuretics
    • Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
    • Oral > Solid: 25 mg
  431. Streptokinase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
  432. Streptomycin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
  433. Succimer General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
  434. Sulfadiazine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
  435. Sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 500 mg + 25 mg tablet
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    • Oral > Solid: 250 mg + 12.5 mg tablet
  436. Sulfamethoxazole + trimethoprim General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    Indications
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
  437. Sulfasalazine General information
    Section
    Disease-modifying agents used in rheumatoid disorders (DMARDs)
    • Oral > Solid: 500 mg
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema:
  438. Suramin sodium General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
  439. Surfactant General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation
  440. Suxamethonium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial
  441. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
  442. Telmisartan + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
  443. Telmisartan + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
  444. Tenofovir disoproxil fumarate General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
  445. Terbinafine General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
  446. Testosterone General information
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
  447. Tetanus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  448. Tetracaine General information
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
    Indications
  449. Tetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
  450. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
  451. Thiamine General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg (hydrochloride)
  452. Tick-borne encephalitis vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
  453. Timolol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
  454. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
  455. Tiotropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 18 µg capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation
  456. Tranexamic acid General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
  457. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
  458. Triclabendazole General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid: 250 mg tablet
  459. Tropicamide General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
  460. Tuberculin, purified protein derivative General information
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
  461. Typhoid vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  462. Ulipristal General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
  463. Urea General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
  464. Valaciclovir General information
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir for Herpes simplex infections Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella
  465. Valganciclovir General information
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL powder for oral solution
    • Oral > Solid: 450 mg Tablet
  466. Valproic acid General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 200 mg per 5 mL (sodium valproate)
    • Oral > Solid: 200 mg (sodium valproate) enteric-coated tablet; 500 mg (sodium valproate) enteric-coated tablet; 100 mg (sodium valproate) crushable tablet
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule (sodium valproate); 100 mg per mL in 10 mL ampoule (sodium valproate)
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 200 mg enteric-coated (sodium valproate); 500 mg enteric-coated (sodium valproate)
  467. Vancomycin General information
    Section
    Watch group antibiotics
    • Oral > Solid: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
  468. Varicella vaccine General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  469. Vecuronium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
  470. Verapamil General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
  471. Vinblastine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
  472. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
  473. Voriconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
  474. Warfarin General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)
  475. Water for injection General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
  476. Whole blood General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  477. Xylometazoline General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL
    Indications
  478. Yellow fever vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
  479. Zidovudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 250 mg capsule; 300 mg tablet
  480. Zinc sulfate General information
    Section
    Medicines for diarrhoea
    • Oral > Solid: 20 mg
    Indications
  481. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle